Moreover, an early-phase clinical trial revealed that combining the PARPi olaparib and the PD-L1 inhibitor durvalumab was considered tolerable and demonstrated clinical activity in patients with advanced women’s cancers, signifying potential synergy between PARPis and ICIs in overcoming PARPi resistance [65]. This evidence concerns the gene CD274 and cancer.